Afatinib in advanced refractory urothelial cancer

Brief description of study

If you have been diagnosed with urothelial cancer (a type of bladder cancer), which cannot be removed surgically at this time and has grown after treatment with standard first-line chemotherapy containing a platinu drug, such as cisplatin or carbopiatin, you may be qualified for this study. The main goal of this study is to find out what effects the experi ental drug BIBW 2992 (also called afatinib) has on you and your advanced urothelial cancer with molecular alterations (changes in your genes) in Epidermal Growth Factor (EGF) and Human Epidermal Growth Factor Receptor (HER2) specifically, EGFR, HER2, ERBB3, or ERBB4.

Clinical Study Identifier: s17-01711 Identifier: NCT02122172
Principal Investigator: Arjun Vasant Balar.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.